Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours.

Jordi Rodon AhnertGuillem ArgilésRoisin M ConnollyUlka VaishampayanMaja de JongeElena GarraldaMarios GiannakisDavid C SmithJason R DobsonMargaret E McLaughlinAbdelkader SeroutouYan JiJennifer MorawiakSusan E MoodyFilip Janku

Published in: British journal of cancer (2021)

NCT01351103.

Keyphrases

open label
cell proliferation
stem cells
double blind
clinical trial